Castalysis Bioscience

Castalysis Bioscience is a private Shanghai-based biotech developing in vivo gene editing therapeutics built around its proprietary ultra-compact alphaCas (also referred to as Cas12n) editor. The company is focused on translating this editor into one-time, potentially durable treatments for genetic and chronic diseases, and has also referenced infectious disease applications. Its platform combines miniature gene editors, AI-assisted editor discovery and enzyme engineering, and non-viral in vivo delivery, with capabilities spanning both gene knockout and gene knock-in. Castalysis was incubated by ShanghaiTech University and has licensed core patent assets from the university for commercialization. As of 2026, the company appears to remain at the preclinical stage, with some programs reported to have advanced to preclinical candidate work and financing intended to support investigator-initiated clinical research preparation.